Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge ABSTU:GTN +0.68%76 EV-to-FCF is 18.53 as of Jul. 27, 2026, which is 12% below its 10-year median of 21.16. GuruFocus rates STU:GTN with a GF Score™ of 76/100 and a GF Value™ of €18.51 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 416 Medical Devices & Instruments companies, Getinge AB ranks better than 59.62% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Getinge AB's Enterprise Value is €6,467 Mil.
Getinge AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €349 Mil. Therefore, Getinge AB's EV-to-FCF for today is 18.53.
The historical rank and industry rank for Getinge AB's EV-to-FCF or its related term are showing as below:
STU:GTN'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.25 Med: 21.16 Max: 66.8
Current: 18.88
During the past 13 years, the highest EV-to-FCF of Getinge AB was 66.80. The lowest was 9.25. And the median was 21.16.
STU:GTN's EV-to-FCF is ranked better than 59.62% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 22.955
vs STU:GTN: 18.88
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Getinge AB's share price for today is €20.75.
Getinge AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Getinge AB EV-to-FCF Related Terms
Getinge AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Getinge AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Getinge AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getinge AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Getinge AB's EV-to-FCF falls into.
Getinge AB's current Enterprise Value is €6,467 Mil.
Getinge AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €349 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getinge AB (STU:GTN) has a EV-to-FCF of 18.53 as of Jul. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Getinge AB and its competitors. This is 12% below median its historical median of 21.16. Over the past decade, Getinge AB's EV-to-FCF has ranged from 9.25 to 66.80. According to the industry distribution chart, Getinge AB ranks #168 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 40.4%.
Is Getinge AB's EV-to-FCF too high?
Getinge AB's current EV-to-FCF of 18.53 is 12% below median its 10-year median of 21.16. Over the past 10 years, this metric has ranged from a low of 9.25 to a high of 66.80. The Medical Devices & Instruments industry median EV-to-FCF is 22.96. Getinge AB's value of 18.53 is 19.3% below this industry median. Based on the distribution chart, Getinge AB ranks #168 out of 416 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Getinge AB has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #168 out of 416 companies for EV-to-FCF. This puts Getinge AB in the upper half of its industry. The industry median EV-to-FCF is 22.96. Getinge AB's value of 18.53 is 19.3% below this benchmark. Historically, Getinge AB's own EV-to-FCF has ranged from 9.25 to 66.80 over the past decade. While the company's 10-year median is 21.16 vs. the industry median of 22.96, Getinge AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.96, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getinge AB's current EV-to-FCF of 18.53 is 19.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Getinge AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current EV-to-FCF is 18.53, which is 12% below median its own 10-year median of 21.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (STU:GTN) is currently considered Modestly Overvalued. The stock's GF Value™ is €18.51, compared to a current price of €20.75 — trading 12.1% above its estimated fair value. The current EV-to-FCF is 18.53, which is 12% below median its 10-year median of 21.16 and 19.3% below the Medical Devices & Instruments industry median of 22.96. Getinge AB's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Getinge AB (STU:GTN), the current EV-to-FCF is 18.53 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (STU:GTN) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of €20.75 is trading 12.1% above its estimated GF Value™ of €18.51.
GuruFocus considers Getinge AB to be Modestly Overvalued.
Key valuation signals for STU:GTN:
EV-to-FCF: 18.53 (12% below median its 10-year median of 21.16)
GF Value™: €18.51 vs. price of €20.75 (12.1% above fair value)
Industry Position: 19.3% below the Medical Devices & Instruments median (#168 of 416)
No single metric tells the full story. See the STU:GTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
76GF Score
Get the complete analysis for STU:GTN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:GTN has been successfully added to your 
